Developing differentiated & improved therapies
who have limited treatment options
ValenzaBio is a privately held clinical-stage biopharmaceutical company developing safe, effective, and differentiated therapies for autoimmune and inflammatory diseases. The company’s pipeline of monoclonal antibodies features best-in-class properties, targeting clinically validated mechanisms, and will provide improved treatment options for patients.
Explore our lead product candidates
An anti-IGF-1R monoclonal antibody with a lead indication for thyroid eye diseasemore
An anti-CD19 monoclonal antibody currently enrolling clinical trials in renal autoimmune indicationsmore
An anti-c-KIT monoclonal antibody with a lead indication for chronic urticariamore